AU2016255611B2 - T cell which expresses a gamma-delta T cell receptor (TCR) and a chimeric antigen receptor (CAR) - Google Patents

T cell which expresses a gamma-delta T cell receptor (TCR) and a chimeric antigen receptor (CAR) Download PDF

Info

Publication number
AU2016255611B2
AU2016255611B2 AU2016255611A AU2016255611A AU2016255611B2 AU 2016255611 B2 AU2016255611 B2 AU 2016255611B2 AU 2016255611 A AU2016255611 A AU 2016255611A AU 2016255611 A AU2016255611 A AU 2016255611A AU 2016255611 B2 AU2016255611 B2 AU 2016255611B2
Authority
AU
Australia
Prior art keywords
cell
ser
leu
car
pro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2016255611A
Other languages
English (en)
Other versions
AU2016255611A1 (en
Inventor
John Anderson
Jonathan Fisher
Kenth Gustafsson
Martin PULÉ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
UCL Business Ltd
Original Assignee
UCL Business Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by UCL Business Ltd filed Critical UCL Business Ltd
Publication of AU2016255611A1 publication Critical patent/AU2016255611A1/en
Assigned to UCL BUSINESS LTD reassignment UCL BUSINESS LTD Amend patent request/document other than specification (104) Assignors: UCL BUSINESS PLC
Application granted granted Critical
Publication of AU2016255611B2 publication Critical patent/AU2016255611B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4256—Tumor associated carbohydrates
    • A61K40/4258—Gangliosides, e.g. GM2, GD2 or GD3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/27—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by targeting or presenting multiple antigens
    • A61K2239/28—Expressing multiple CARs, TCRs or antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/27—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by targeting or presenting multiple antigens
    • A61K2239/29—Multispecific CARs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/599—Cell markers; Cell surface determinants with CD designations not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2016255611A 2015-04-30 2016-04-29 T cell which expresses a gamma-delta T cell receptor (TCR) and a chimeric antigen receptor (CAR) Active AU2016255611B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1507368.7 2015-04-30
GBGB1507368.7A GB201507368D0 (en) 2015-04-30 2015-04-30 Cell
PCT/GB2016/051235 WO2016174461A1 (en) 2015-04-30 2016-04-29 T cell which expresses a gamma-delta t cell receptor (tcr) and a chimeric antigen receptor (car)

Publications (2)

Publication Number Publication Date
AU2016255611A1 AU2016255611A1 (en) 2017-11-02
AU2016255611B2 true AU2016255611B2 (en) 2021-08-05

Family

ID=53488907

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2016255611A Active AU2016255611B2 (en) 2015-04-30 2016-04-29 T cell which expresses a gamma-delta T cell receptor (TCR) and a chimeric antigen receptor (CAR)

Country Status (16)

Country Link
US (2) US20180125890A1 (OSRAM)
EP (1) EP3288567B1 (OSRAM)
JP (1) JP6986449B2 (OSRAM)
KR (1) KR20180020140A (OSRAM)
CN (1) CN107771215A (OSRAM)
AU (1) AU2016255611B2 (OSRAM)
BR (1) BR112017023409A2 (OSRAM)
CA (1) CA2982532C (OSRAM)
EA (1) EA201792042A1 (OSRAM)
ES (1) ES3018558T3 (OSRAM)
GB (1) GB201507368D0 (OSRAM)
HK (1) HK1252235A1 (OSRAM)
IL (1) IL255186B (OSRAM)
SG (1) SG11201708402UA (OSRAM)
WO (1) WO2016174461A1 (OSRAM)
ZA (1) ZA201706923B (OSRAM)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201505858VA (en) 2013-01-28 2015-09-29 St Jude Childrens Res Hospital A chimeric receptor with nkg2d specificity for use in cell therapy against cancer and infectious disease
EP3805371A1 (en) 2014-05-15 2021-04-14 National University of Singapore Modified natural killer cells and uses thereof
GB201506423D0 (en) * 2015-04-15 2015-05-27 Tc Biopharm Ltd Gamma delta T cells and uses thereof
GB201507368D0 (en) 2015-04-30 2015-06-17 Ucl Business Plc Cell
US10426797B2 (en) * 2017-03-24 2019-10-01 Lentigen Technology, Inc. Compositions and methods for treating cancer with anti-CD33 immunotherapy
IL269553B2 (en) 2017-03-27 2025-10-01 Nat Univ Singapore Truncated NKG2D chimeric receptors and their uses in immunotherapy with natural killer cells
MX2019011570A (es) 2017-03-27 2019-11-18 Nat Univ Singapore Lineas celulares estimuladoras para expansion y activacion ex vivo de celulas asesinas naturales.
JP2020530993A (ja) * 2017-08-02 2020-11-05 オートラス リミテッド キメラ抗原受容体または改変ｔｃｒを発現し、選択的に発現されるヌクレオチド配列を含む細胞
EP3687555A4 (en) * 2017-09-27 2021-07-21 Ohio State Innovation Foundation CAR-NK CELL THERAPY AND CAR-T TISSUE FACTOR TARGETING
GB201715918D0 (en) * 2017-09-29 2017-11-15 Tc Biopharm Ltd Modified CAR-T
GB201720949D0 (en) 2017-12-15 2018-01-31 Autolus Ltd Cell
US12258381B2 (en) 2018-02-09 2025-03-25 National University Of Singapore Activating chimeric receptors and uses thereof in natural killer cell immunotherapy
GB201804701D0 (en) * 2018-03-23 2018-05-09 Gammadelta Therapeutics Ltd Lymphocytes expressing heterologous targeting constructs
CN112055717B (zh) 2018-04-02 2024-04-26 新加坡国立大学 用在免疫细胞中表达的膜结合抗细胞因子非信号传导粘合剂中和人细胞因子
CN110343712B (zh) * 2018-04-04 2023-12-26 达仁生物科技有限公司 嵌合抗原受体和其治疗肺癌的方法
SG11202010154UA (en) * 2018-04-18 2020-11-27 Ucl Business Ltd Method for enhancing the suppressive properties of treg cells
CN108588023B (zh) * 2018-05-09 2020-02-14 河北森朗生物科技有限公司 一种生产嵌合抗原受体修饰的γδT细胞的方法
CN110577932A (zh) * 2018-06-07 2019-12-17 亘喜生物科技（上海）有限公司 一种脐带血来源的嵌合抗原受体t细胞
WO2019242632A1 (en) * 2018-06-19 2019-12-26 1§1Nanjing Legend Biotech Co., Ltd. Engineered cells and uses thereof
WO2020027094A1 (ja) 2018-07-31 2020-02-06 サイアス株式会社 ｉＰＳ細胞を介して再生Ｔ細胞集団を製造する方法
WO2020033464A1 (en) * 2018-08-07 2020-02-13 H. Lee Moffitt Cancer Center And Research Institute Inc. Car t-cells for the treatment of bone metastatic cancer
TW202016293A (zh) * 2018-08-10 2020-05-01 國立大學法人京都大學 Ｃｄ３陽性細胞的製造方法
EP3844186A4 (en) 2018-08-29 2022-08-17 National University of Singapore METHOD OF SPECIFIC STIMULATION OF SURVIVAL AND EXPANSION OF GENETICALLY MODIFIED IMMUNE CELLS
US12077586B2 (en) * 2018-09-19 2024-09-03 LAVA Therapeutics N.V. Bispecific antibodies for use in the treatment of hematological malignancies
CN109234236A (zh) * 2018-09-29 2019-01-18 吉林大学第医院 一种嵌合抗原受体γδT细胞的制备方法
WO2020072536A1 (en) * 2018-10-01 2020-04-09 Adicet Bio, Inc. COMPOSITIONS AND METHODS REGARDING ENGINEERED AND NON- ENGINEERED γδ-Τ CELLS FOR TREATMENT OF HEMATOLOGICAL TUMORS
KR20210087458A (ko) * 2018-10-01 2021-07-12 아디셋 바이오, 인크. 고형 종양 치료를 위한 조작된 및 비-조작된 γδ-T 세포에 관한 조성물 및 방법
EP3919515A4 (en) 2019-01-29 2022-11-23 Shanghai Jiao Tong University CHIMERIC ANTIGEN RECEPTOR AND USE THEREOF
WO2020172555A1 (en) * 2019-02-21 2020-08-27 Regents Of The University Of Minnesota Genetically modified gamma delta t cells and methods of making and using
KR20210137085A (ko) 2019-03-05 2021-11-17 엔카르타, 인크. Cd19 유도된 키메라 항원 수용체 및 면역 요법에서 이의 용도
JP2022526841A (ja) * 2019-04-12 2022-05-26 フェインズ セラピューティクス，インコーポレーテッド ヒト化抗葉酸受容体１キメラ抗原受容体及びその使用
CN113728095A (zh) * 2019-04-22 2021-11-30 南京传奇生物科技有限公司 工程化的细胞及其用途
JPWO2020251046A1 (OSRAM) 2019-06-14 2020-12-17
JP2022537066A (ja) * 2019-06-21 2022-08-23 シャタック ラボ，インコーポレイテッド キメラタンパク質を発現するｔ細胞
GB201909283D0 (en) * 2019-06-27 2019-08-14 Cancer Research Tech Ltd Fusion proteins with enzyme activity
CN110981972B (zh) * 2019-12-25 2022-09-30 华夏源（上海）细胞基因工程股份有限公司 一种分泌双特异性抗体的嵌合抗原受体及其表达载体和应用
BR112022017419A2 (pt) * 2020-03-03 2022-10-18 Janssen Biotech Inc Células t gama-delta e usos das mesmas
CN117844761A (zh) 2020-05-22 2024-04-09 重庆精准生物技术有限公司 逆转肿瘤微环境的融合蛋白及其应用
CN116348485A (zh) 2020-07-17 2023-06-27 英研生物(英国)有限公司 提供用于过继性细胞疗法的靶向共刺激的受体
US12012441B2 (en) 2020-10-26 2024-06-18 Neptune Biosciences Llc Engineered human IL-21 cytokines and methods for using the same
EP4355340A4 (en) 2021-06-16 2025-05-21 Instil Bio, Inc. RECEPTORS FOR TARGETED COSTIMULATION FOR ADOPTIVE CELL THERAPY
EP4370213A4 (en) 2021-07-16 2025-06-04 Instil Bio (Uk) Limited Chimeric molecules for targeted costimulation for adoptive cell therapy
CN113528455A (zh) * 2021-07-19 2021-10-22 广州百暨基因科技有限公司 表达嵌合抗原受体的γδT细胞
CA3233987A1 (en) * 2021-10-06 2023-04-13 Carl NOVINA Engineered cytokine receptors for tunable adoptive cell therapy

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014186469A2 (en) * 2013-05-14 2014-11-20 Board Of Regents, The University Of Texas System Human application of engineered chimeric antigen receptor (car) t-cells
WO2015017214A1 (en) * 2013-07-29 2015-02-05 Bluebird Bio, Inc. Multipartite signaling proteins and uses thereof

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2360046A1 (en) 1999-01-28 2000-08-03 Lawrence S. Lamb, Jr. In vitro activated gamma delta lymphocytes
NZ522337A (en) 2000-04-03 2004-12-24 Hemosol Inc Production of TcR gamma delta T cells
ATE309996T1 (de) 2000-09-11 2005-12-15 Chiron Corp Chinolinonderivate als tyrosin-kinase inhibitoren
JPWO2006006720A1 (ja) 2004-07-13 2008-05-01 株式会社メディネット γδＴ細胞の培養方法、γδＴ細胞及び治療・予防剤
US8153426B2 (en) 2004-08-19 2012-04-10 University College Cardiff Consultants Limited Preparation of antigen-presenting human gamma-delta T cells and use in immunotherapy
WO2008152822A1 (ja) 2007-06-15 2008-12-18 Medinet Co., Ltd. 医薬
PH12013501201A1 (en) 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
WO2013033626A2 (en) * 2011-08-31 2013-03-07 Trustees Of Dartmouth College Nkp30 receptor targeted therapeutics
EP2814846B1 (en) * 2012-02-13 2020-01-08 Seattle Children's Hospital d/b/a Seattle Children's Research Institute Bispecific chimeric antigen receptors and therapeutic uses thereof
WO2013174404A1 (en) * 2012-05-23 2013-11-28 Ganymed Pharmaceuticals Ag Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
US10117896B2 (en) * 2012-10-05 2018-11-06 The Trustees Of The University Of Pennsylvania Use of a trans-signaling approach in chimeric antigen receptors
KR102417657B1 (ko) 2013-02-06 2022-07-07 안트로제네시스 코포레이션 개선된 특이성을 갖는 변경된 t 림프구
WO2014130657A1 (en) * 2013-02-20 2014-08-28 The Trustees Of The University Of Pennsylvania Treatment of cancer using humanized anti-egfrviii chimeric antigen receptor
UY35468A (es) * 2013-03-16 2014-10-31 Novartis Ag Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19
EP3060059A4 (en) 2013-10-25 2017-11-01 Board of Regents, The University of Texas System Polyclonal gamma delta t cells for immunotherapy
WO2015066262A1 (en) * 2013-11-04 2015-05-07 Trustees Of Dartmouth College Methods for preventing toxicity of adoptive cell therapy
EP3071222B1 (en) * 2013-11-21 2020-10-21 UCL Business Ltd Cell
MX369513B (es) * 2014-02-14 2019-11-11 Univ Texas Receptores de antígenos quiméricos y métodos de realización.
GB201403972D0 (en) * 2014-03-06 2014-04-23 Ucl Business Plc Chimeric antigen receptor
EP3593812A3 (en) 2014-03-15 2020-05-27 Novartis AG Treatment of cancer using chimeric antigen receptor
JP2017514471A (ja) * 2014-04-23 2017-06-08 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム キメラ抗原受容体（ｃａｒ）並びにその製造及び使用方法
EP3167050A1 (en) 2014-07-09 2017-05-17 TC Biopharm Ltd. Gamma delta t cells and uses thereof
GB201506423D0 (en) * 2015-04-15 2015-05-27 Tc Biopharm Ltd Gamma delta T cells and uses thereof
WO2016081518A2 (en) 2014-11-17 2016-05-26 Adicet Bio, Inc. Engineered gamma delta t-cells
GB201507368D0 (en) 2015-04-30 2015-06-17 Ucl Business Plc Cell
CN105158466B (zh) 2015-05-05 2017-12-22 中国科学院广州生物医药与健康研究院 一种检测抗cd19的嵌合抗原受体t细胞对白血病细胞抑制作用的方法

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014186469A2 (en) * 2013-05-14 2014-11-20 Board Of Regents, The University Of Texas System Human application of engineered chimeric antigen receptor (car) t-cells
WO2015017214A1 (en) * 2013-07-29 2015-02-05 Bluebird Bio, Inc. Multipartite signaling proteins and uses thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DENIGER, D.C. ET AL, "Bispecific T-cells Expressing Polyclonal Repertoire of Endogenous [gamma][delta] T-cell Receptors and Introduced CD19-specific Chimeric Antigen Receptor", MOLECULAR THERAPY, (2013), vol. 21, no. 3, pages 638 - 647 *

Also Published As

Publication number Publication date
WO2016174461A1 (en) 2016-11-03
IL255186B (en) 2022-02-01
CA2982532C (en) 2023-10-03
JP2018514204A (ja) 2018-06-07
AU2016255611A1 (en) 2017-11-02
SG11201708402UA (en) 2017-11-29
ES3018558T3 (es) 2025-05-16
CN107771215A (zh) 2018-03-06
IL255186A0 (en) 2017-12-31
BR112017023409A2 (pt) 2018-07-24
KR20180020140A (ko) 2018-02-27
US20220211756A1 (en) 2022-07-07
JP6986449B2 (ja) 2021-12-22
US20180125890A1 (en) 2018-05-10
CA2982532A1 (en) 2016-11-03
EP3288567B1 (en) 2025-03-19
US12331316B2 (en) 2025-06-17
EP3288567A1 (en) 2018-03-07
EA201792042A1 (ru) 2018-03-30
HK1252235A1 (zh) 2019-05-24
GB201507368D0 (en) 2015-06-17
ZA201706923B (en) 2022-02-23

Similar Documents

Publication Publication Date Title
AU2016255611B2 (en) T cell which expresses a gamma-delta T cell receptor (TCR) and a chimeric antigen receptor (CAR)
EP3288970B1 (en) Nucleic acid construct for expressing more than one chimeric antigen receptor
RU2717984C2 (ru) Клетка
EP3288969B1 (en) Nucleic acid construct for expressing more than one chimeric antigen receptor
JP2025024103A (ja) Ｍａｇｅ ａ４ ｔ細胞受容体
TW201940506A (zh) Ｎｙｅｓｏ ｔ細胞受體
EP3253783A1 (en) Signalling system
EP3612568A1 (en) Cell
KR102804751B1 (ko) Cxcr5에 결합하는 키메라 항원 수용체 및 car-t 세포
CN111479918A (zh) 细胞
CN114375303B (zh) Magea10特异性t细胞受体及其用途
CN119053618A (zh) 嵌合ilt受体组合物和方法
CN113840834A (zh) Magea1特异性t细胞受体及其用途
CN114555789A (zh) 工程化免疫细胞
JP2024519614A (ja) Ｐｒａｍｅ特異的ｔ細胞受容体とキメラ補助刺激受容体との組合せ
EP3864034A1 (en) Cell
CN106520806B (zh) 一种重组car基因及其载体、car-t细胞和应用
CN116615446A (zh) Mage-a3特异性t细胞受体及其用途
WO2022167798A1 (en) Molecule
KR20240095172A (ko) 항원 특이적 t 세포 수용체 및 키메라 공동자극 수용체의 조합
HK40042687A (en) Nyeso t cell receptor (tcr)

Legal Events

Date Code Title Description
HB Alteration of name in register

Owner name: UCL BUSINESS LTD

Free format text: FORMER NAME(S): UCL BUSINESS PLC

FGA Letters patent sealed or granted (standard patent)